Thermo Fisher Scientific has been active in the market recently. Its Q1 2024 earnings outperformed analyst expectations, which was discussed in a conference call. Several asset management firms like InTrack, ZRC Wealth, and MV Capital have adjusted their holdings in Thermo Fisher while Miracle Mile Advisors and JW Cole Advisors bought new shares. The company's stock experienced both falls and gains, with stock performance arguably following its strong fundamentals. A 17% Compound Annual Growth Rate (CAGR) has been rewarded to Thermo Fisher shareholders over the past five years. Despite being considered 'oversold', there are beliefs that Thermo Fisher's intrinsic value is 26% below its share price. The analysts' price target reduction to $600.00 caused mixed reactions. Thermo Fisher's resilient 2024 performance navigates the economic headwinds and their stocks have been trending. Recently, the company increased its dividend, underwent sustainability efforts for biobased films, and is set to present at BofA securities. It's worth noting that Thermo Fisher is reportedly using its debt reasonably well, and its balance sheet appears robust. Lastly, it's preparing an Investor Day and making moves for expansion, namely in Kentucky.
Thermo Fisher Scientific TMO News Analytics from Tue, 17 Oct 2023 07:00:00 GMT to Fri, 05 Jul 2024 23:57:03 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -5
